Search Results - "Walter, Harriet S"

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy by Eyre, Toby A, Walter, Harriet S, Iyengar, Sunil, Follows, George, Cross, Matthew, Fox, Christopher P, Hodson, Andrew, Coats, Josh, Narat, Santosh, Morley, Nick, Dyer, Martin J S, Collins, Graham P

Get full text

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies by Walter, Harriet S., Rule, Simon A., Dyer, Martin J.S., Karlin, Lionel, Jones, Ceri, Cazin, Bruno, Quittet, Philippe, Shah, Nimish, Hutchinson, Claire V., Honda, Hideyuki, Duffy, Kevin, Birkett, Joseph, Jamieson, Virginia, Courtenay-Luck, Nigel, Yoshizawa, Toshio, Sharpe, John, Ohno, Tomoya, Abe, Shinichiro, Nishimura, Akihisa, Cartron, Guillaume, Morschhauser, Franck, Fegan, Christopher, Salles, Gilles

“…We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with…”
Get full text

Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma by Alqahtani, Abdullah N. M., Jayne, Sandrine, Ahearne, Matthew J., Trethewey, Christopher S., Duraisingham, Sai S., Lehmann, Susann, Cowley, Caroline M., Dyer, Martin J. S., Walter, Harriet S.

Get full text

Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia by Jackson, Ross A., Smith, Victoria M., Jayne, Sandrine, Drewes, Cosima, Bens, Susanne, Siebert, Reiner, Dyer, Martin J. S., Walter, Harriet S.

Get full text

Targeting anti‐apoptotic BCL2 family proteins in haematological malignancies – from pathogenesis to treatment by Vogler, Meike, Walter, Harriet S., Dyer, Martin J. S.

“…Summary The B‐cell lymphoma 2 (BCL2) family of proteins comprise key regulators of apoptosis and are implicated in the pathogenesis of many malignancies,…”
Get full text

Limitations of Monitoring Disease Progression Using Circulating Tumor DNA in Lymphoma: An Example From Primary Cutaneous DLBCL Leg‐type by Trethewey, Christopher S., Walter, Harriet S., Alqahtani, Abdullah N. M., Schmid, Ralf, Guttery, David S., Griffin, Yvette, Ahearne, Matthew J., Saldanha, Gerald S., Jayne, Sandrine P. N., Dyer, Martin J. S.

Get full text

BCL2 inhibition: back to the future by Dyer, Martin J. S., Walter, Harriet S.

Get full text

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer by Jones, Robert, Plummer, Ruth, Moreno, Victor, Carter, Louise, Roda, Desamparados, Garralda, Elena, Kristeleit, Rebecca, Sarker, Debashis, Arkenau, Tobias, Roxburgh, Patricia, Walter, Harriet S, Blagden, Sarah, Anthoney, Alan, Klencke, Barbara J, Kowalski, Mark M, Banerji, Udai

“…This was a Phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to establish…”
Get full text

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia by Danilov, Alexey V, Herbaux, Charles, Walter, Harriet S, Hillmen, Peter, Rule, Simon A, Kio, Ebenezer A, Karlin, Lionel, Dyer, Martin J S, Mitra, Siddhartha S, Yi, Ping Cheng, Humeniuk, Rita, Huang, Xi, Zhou, Ziqian, Bhargava, Pankaj, Jürgensmeier, Juliane M, Fegan, Christopher D

“…Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of…”
Get full text

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia by Flinn, Ian W., Gribben, John G., Dyer, Martin J.S., Wierda, William, Maris, Michael B., Furman, Richard R., Hillmen, Peter, Rogers, Kerry A., Iyer, Swaminathan Padmanabhan, Quillet-Mary, Anne, Ysebaert, Loic, Walter, Harriet S., Verdugo, Maria, Klein, Christian, Huang, Huang, Jiang, Yanwen, Lozanski, Gerard, Pignataro, Daniela Soriano, Humphrey, Kathryn, Mobasher, Mehrdad, Kipps, Thomas J.

“…This single-arm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD) of venetoclax when given with obinutuzumab and its safety and…”
Get full text

The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion by Jayne, Sandrine, López, Cristina, Put, Natalie, Nagel, Inga, Lierman, Els, Penas, Eva Maria Murga, Michaux, Lucienne, Ahearne, Matthew J, Walter, Harriet S, Bens, Susanne, Drewes, Cosima, Szczepanowski, Monika, Schlesner, Matthias, Rosenstiel, Philip, Wlodarska, Iwona, Siebert, Reiner, Dyer, Martin J S

“…The chromosomal translocation t(1;6)(p35.3;p25.2) is a rare but recurrent aberration in chronic lymphocytic leukaemia (CLL). We report molecular…”
Get full text

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059 by Walter, Harriet S., Jayne, Sandrine, Rule, Simon A., Cartron, Guillaume, Morschhauser, Franck, Macip, Salvador, Karlin, Lionel, Jones, Ceri, Herbaux, Charles, Quittet, Philippe, Shah, Nimish, Hutchinson, Claire V., Fegan, Christopher, Yang, Yingsi, Mitra, Siddhartha, Salles, Gilles, Dyer, Martin J.S.

Get full text

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study by Jafri, Mariam, Kristeleit, Hartmut, Misra, Vivek, Baxter, Mark, Ahmed, Samreen, Jegannathen, Apurna, Jain, Ankit, Maskell, David, Barthakur, Urmila, Edwards, Gwenllian, Walter, Harriet S, Walshaw, Richard, Khan, Madeha, Borley, Annabel, Rea, Daniel

“…This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK…”
Get more information

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma by Morschhauser, Franck, Dyer, Martin J. S., Walter, Harriet S., Danilov, Alexey V., Ysebaert, Loic, Hodson, Daniel James, Fegan, Christopher, Rule, Simon A., Radford, John, Cartron, Guillaume, Bouabdallah, Krimo, Davies, Andrew John, Spurgeon, Stephen, Rajakumaraswamy, Nishanthan, Li, Biao, Humeniuk, Rita, Huang, Xi, Bhargava, Pankaj, Jürgensmeier, Juliane M., Salles, Gilles

Get full text

Chronic lymphocytic leukaemia therapy: is less more? by Walter, Harriet S, Dyer, Martin J S

Get full text

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia by Eyre, Toby A., Roeker, Lindsey E., Fox, Christopher P., Gohill, Satyen H., Walewska, Renata, Walter, Harriet S., Forconi, Francesco, Broom, Angus, Arumainathan, Arvind, Brander, Danielle M., Allan, John N., Schuster, Stephen J., Hill, Brian T., Lansigan, Frederick, Cheson, Bruce D., Lamanna, Nicole, Coombs, Catherine C., Barr, Paul M., Skarbnik, Alan P., Shadman, Mazyar, Ujjani, Chaitra S., Pearson, Laurie, Pagel, John M., Jacobs, Ryan, Mato, Anthony R.

“…Summary Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase…”
Get full text

Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma by Feeney, Laura, Jain, Yatin, Beasley, Matthew, Donnelly, Oliver, Kong, Anthony, Moleron, Rafael, Nallathambi, Chandran, Rolles, Martin, Sanghera, Paul, Tin, Aung, Ulahannan, Danny, Walter, Harriet S., Webster, Richard, Metcalf, Robert

“…Adenoid cystic carcinoma (ACC) is a rare cancer of secretory glands. Recurrent or metastatic (R/M) ACC is generally considered resistant to cytotoxic…”
Get full text

New Agents to Treat Chronic Lymphocytic Leukemia by Walter, Harriet S, Salles, Gilles A, Dyer, Martin J S

Get full text

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen by Thompson, Meghan C., Harrup, Rosemary A., Coombs, Catherine C., Roeker, Lindsey E., Pu, Jeffrey J., Choi, Michael Y., Barr, Paul M., Allan, John N., Šimkovič, Martin, Leslie, Lori, Rhodes, Joanna, Chong, Elise A., Kamdar, Manali, Skarbnik, Alan, Lansigan, Frederick, McCall, Brittany, Saja, Khalid, Dyer, Martin J.S., Walter, Harriet S., Lefebure, Marcus, Thadani-Mulero, Maria, Boyer, Michelle, Biondo, Juliana, Sail, Kavita, Manzoor, Beenish S., Furman, Richard, Bantilan, Kurt S., Goy, Andre, Feldman, Tatyana, Labella, Dominic, Schuster, Stephen J., Park, Jae, Palomba, Lia, Zelenetz, Andrew, Eyre, Toby A., Kater, Arnon P., Seymour, John F., Mato, Anthony R.

Get full text

Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines by Kozaki, Ryohei, Vogler, Meike, Walter, Harriet S, Jayne, Sandrine, Dinsdale, David, Siebert, Reiner, Dyer, Martin J S, Yoshizawa, Toshio

“…Bruton's tyrosine kinase (BTK) is a key regulator of the B-cell receptor signaling pathway, and aberrant B-cell receptor (BCR) signaling has been implicated in…”
Get full text